Commodore Capital LP recently announced the acquisition of new stake in Harpoon Therapeutics Inc (NASDAQ:HARP). This fresh investment now brings its stake to 10.06% valued currently at $18.06 million. In addition, Citadel Advisors LLC raised its holdings by 0.98 million to 1.03 million shares. And Cormorant Asset Management LP has lifted its position by 1,534.52% or 0.83 million shares – to 0.88 million shares.
With over 8.26 million Harpoon Therapeutics Inc (HARP) shares trading Monday and a closing price of $22.36 on the day, the dollar volume was approximately $184.8 million. The shares have shown a positive half year performance of 166.19% and its price on 01/08/24 gained nearly 111.94%. Currently, there are 16.93M common shares owned by the public and among those 11.82M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Harpoon Therapeutics Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and abrdn Life Sciences Investors. Vanguard Total Stock Market ETF owns 69106.0 shares of the company’s stock, all valued at over $0.73 million. abrdn Life Sciences Investors now owns shares totaling to 0.15% of the shares outstanding.
Shares of Harpoon Therapeutics Inc (NASDAQ: HARP) opened at $22.30, up $11.75 from a prior closing price of $10.55. However, the script later moved the day high at 22.45, up 111.94%. The company’s stock has a 5-day price change of 96.66% and 499.46% over the past three months. HARP shares are trading 96.66% year to date (YTD), with the 12-month market performance up to 179.50% higher. It has a 12-month low price of $3.11 and touched a high of $15.19 over the same period. HARP has an average intraday trading volume of 222.84K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 111.92%, 142.06%, and 200.46% respectively.
Institutional ownership of Harpoon Therapeutics Inc (NASDAQ: HARP) shares accounts for 25.82% of the company’s 16.93M shares outstanding. Mutual fund holders own 11.84%, while other institutional holders and individual stakeholders account for 24.76% and 1.06% respectively.
It has a market capitalization of $378.55M and a beta (3y monthly) value of 2.09. The earnings-per-share (ttm) stands at -$8.71. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.96% over the week and 10.07% over the month.
Analysts forecast that Harpoon Therapeutics Inc (HARP) will achieve an EPS of -$0.74 for the current quarter, -$0.82 for the next quarter and -$4.18 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.14 while analysts give the company a high EPS estimate of -$0.32. Comparatively, EPS for the current quarter was -$5.5 a year ago. Earnings per share for the fiscal year are expected to increase by 89.39%, and -73.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate Harpoon Therapeutics Inc (HARP) as a “Moderate Buy” at a consensus score of 2.14. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 4 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the HARP, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on January 05, 2024, with the firm’s price target at $23.
